Objectives. Opioid treatment of chronic noncancer pain (CNCP) adds complexity and uncertainty to patient interactions. We sought to assess clinician attitudes, beliefs, practice styles, and concerns around opioid prescribing following the release of the US Centers for Disease Control and Prevention (CDC) guideline for prescribing opioids for chronic pain.
Introduction
In the United States, 126.1 million adults (55.8%) report having pain in the previous three months and 25.3 million adults (11.2%) suffer chronic daily pain [1] . The prevalence of chronic noncancer pain (CNCP) in the primary care setting ranges from 5% to 33% [2] . Opioids are commonly prescribed for CNCP [3] . The number of opioid prescriptions increased from approximately 76 million in 1991 to 207 million in 2013 [4] .
The current opioid crisis has both increased the burden on clinicians to effectively and safely manage opioid prescribing and has complicated clinician-patient interactions. Previous surveys suggest that opioid prescribing is a problem for patients and providers. In a survey of 56 primary care providers, over 80% of respondents felt that managing patients with chronic pain was stressful and worried about medication misuse and addiction [5] . In a survey of 216 Wisconsin physicians, 54% of respondents thought opioid diversion and abuse was a moderate or serious problem [6] . In a survey of 111 primary care providers, fear of addiction and drug diversion were the strongest barriers to prescribing opioids, and provider satisfaction with the treatment of chronic pain was low [7] .
In March 2016, the US Centers for Disease Control and Prevention (CDC) released a guideline targeted at primary care clinicians prescribing opioids for chronic pain outside of active cancer treatment, palliative care, and end-of-life care [8] . The CDC guideline makes 12 recommendations, which include avoiding coprescription of opioids and benzodiazepines, using the Prescription Drug Monitoring Program (PDMP), and offering naloxone when prescribing opioids to patients at increased risk for overdose. This guideline has been met with controversy in the medical community [9] and may have an uncertain impact on opioid prescribing and pain management [10] . Little is known about the extent to which clinicians are following prescribing practices outlined in the guideline.
We conducted a survey of opioid prescribing practices among clinicians practicing at a large academic institution. We were interested in assessing current attitudes, beliefs, practice styles, and concerns around opioid prescribing in the wake of the release of the CDC guideline.
Methods

Study Population
We conducted a web-based survey (Qualtrics, Provo, UT, USA) of clinical staff members at the Mayo Clinic, a multispecialty medical practice in Rochester, Minnesota. The dean of clinical practice e-mailed an invitation to 2,387 physicians, nurse practitioners (NPs), and physican assistants (PAs). A link to the survey was provided and remained open for completion between September 19, 2016, and October 17, 2016. Respondents exited the survey upon indication of not prescribing opioids or if they were currently trainees in residency.The Mayo Institutional Review Board reviewed the project and noted that the application is a quality improvement project and determined that it does not constitute research as defined under 45 CFR 46.102.
Questionnaire
The 29-item survey addressed the following areas:
Clinician Characteristics
We assessed clinician licensure (MD/DO/MBBS, NP/PA, DDS/DMD), medical specialty, age, gender, years in practice, and percentage of patients prescribed opioids for chronic noncancer pain (CNCP) and cancer or endof-life pain. We selected these variables because prescribing patterns for other medications may differ by licensure [11] and opioid prescribing may differ by gender and age [12] . We also assessed clinician knowledge of a patient requiring medical attention or dying from an opioid overdose, enrollment in a PDMP, awareness of the CDC guideline for opioid prescribing for CNCP, and whether additional education had been sought for assistance with opioid prescribing practices.
Attitudes and Beliefs
We assessed clinician confidence in their ability to care for patients with CNCP, attitudes about the effectiveness of opioids for CNCP and their satisfaction with the clinical care of CNCP patients, and consistency in the clinical approach to opioid prescribing.
Practice Styles and Provider Concerns
We assessed practice styles regarding depression and substance abuse screening, benzodiazepine and naloxone prescribing, and influence of patient satisfaction measures on prescription practices. We inquired about patient misuse ("taking in higher doses"), dependence ("development of tolerance and the potential for withdrawal on discontinuation"), addiction ("drug craving, obsessive thinking about the drug, loss of control, and compulsive use"), and perceptions of being manipulated.
Statistical Analyses
We summarized provider characteristics using summary statistics. Respondent count and proportion were calculated based on total respondents per question, and the number skipping a question was not included in the denominator.
Chi-square tests of independence were used to determine differences in responses for providers who indicated that they knew of a patient who required medical attention for an opioid overdose (i.e., "knowledge of a patient who required medical attention for opioid overdose") and who indicated that they were aware of the CDC guideline for prescribing opioids for CNCP, with the questions related to provider enrollment in the PDMP (Table 1) , attitudes and beliefs (Table 2) , and practice styles and provider concerns (Table 3) . Responses were grouped using the two top categories for each response scale (agree and strongly agree; always and frequently; and very satisfied and somewhat satisfied) compared with all response options combined. Relative rates (ratio of two proportions) with associated 95% confidence intervals were calculated for each association. All data management and statistical analyses were performed using Statistical Analysis Software (SAS) Version 9.3 (Cary, NC, USA).
Results
Survey Response
Nine hundred sixty-one clinicians followed the link to the online survey (response rate ¼ 40%, 961/2,387), of whom 720 reported prescribing opioids and were not currently in medical residency.
Demographics
Sixty-five percent were physicians, and 35% were NP/ PAs with a mean age of 47 years (range ¼ 25-84 years) ( Table 1) . Thirty-two percent of respondents reported that more than 25% of their patients had been prescribed opioids for CNCP. Nineteen percent knew of a patient who had had an overdose event, and 5% knew of a patient who died from an overdose. Fifty-five percent were enrolled in the state PDMP, 67% were aware of the CDC guideline for prescribing opioids for CNCP, and 47% had sought medical education to improve their opioid prescribing practices. Clinicians who knew of a patient who required medical attention for an opioid overdose were more likely to be enrolled in the PDMP (68.0% vs 51.8%, relative rate [RR] ¼ 1.31, 95% confidence interval [CI] ¼ 1.14-1.52, chi-square ¼ 11.00, P < 0.01).
Attitudes and Beliefs
Forty-seven percent of clinicians were confident in their ability to care for patients with CNCP (Table 2) . Sixtytwo percent did not believe that opioids were effective for CNCP, and 82% were reluctant to prescribe them for this indication. Forty-five percent were satisfied with the care that patients obtaining opioids for CNCP were receiving. Nearly all (94%) respondents believed that it was important to have a consistent approach to opioid prescribing. Awareness of the CDC guideline was higher among providers with more confidence in caring for patients with CNCP (74% vs 61%, RR ¼ 1.21, 95% CI ¼ 1.09-1.35, chi-square ¼ 12.4, P < 0.01). Clinicians reporting awareness of the CDC guideline were less likely to believe that opioids were effective for CNCP (14% vs 
Practice Styles and Provider Concerns
Seventy-four percent of respondents reported that they follow the CDC guideline for prescribing opioids for chronic pain (Table 3) . Sixty-three percent screened their patients for substance use disorder before starting opioids, and 41% screened for depression. Seventy percent do not prescribe benzodiazepines and opioids concurrently, and only 2% always or frequently prescribed naloxone. Twelve percent reported that concerns that patient satisfaction influenced decisions to prescribe opioids. Clinicians who indicated awareness of the CDC guideline were twice as likely to report always or frequently screening their patients for depression (49% vs 24%, RR ¼ 2.05, 95% CI ¼ 1.59-2.64, chi-square ¼ 39.1, P < 0.01) and were more likely to report always or frequently screening their patients for substance abuse (68% vs 50%, RR ¼ 1.35, 95% CI ¼ 1.17-1.56, chi-square ¼ 20.1, P < 0.01). These clinicians were also 44% less likely to report prescribing their patients concomitant opioids and benzodiazepines (7% vs 13%, RR ¼ 0.56, 95% CI ¼ 0.35-0.89, chi-square ¼ 6.1,
Sixty-six percent worried about dependence among patients receiving opioids. Fifty-eight percent worried about patient addiction. Clinicians who knew of a patient with an opioid overdose event were more likely to express concerns regarding patient dependence (78.2% vs 62.7%, RR ¼ 1.25, 95% CI ¼ 1.11-1.40, P < 0.01) and addiction to opioids (71.8% vs 54.7%, RR ¼ 1.31, 95% CI ¼ 1.15-1.50, P < 0.01). Clinicians who reported awareness of the CDC guideline were more likely to express worry over their patients becoming dependent on opioids (68% vs 60%, RR ¼ 1.14, 95% CI ¼ 1.004-1.30, chi-square ¼ 4.5, P ¼ 0.03).
Discussion
We observed that less than one-half of clinicians were confident in their ability to care for patients with CNCP, sought medical education to improve their opioid prescribing practices, or were satisfied with the care that patients receiving opioids for CNCP were receiving. A minority endorsed that concerns for patient satisfaction influenced decisions to prescribe opioids. Threequarters reported that they followed the CDC guideline for prescribing opioids for chronic pain; however, just over one-half reported enrollment in the state PDMP and few reported prescribing naloxone. A majority worried about dependence and addiction among patients receiving opioids. This concern was greater among clinicians who knew of patients who had an overdose event. Awareness of the CDC guideline was associated with greater confidence in caring for CNCP patients and increased concern over patients becoming dependent on opioids.
Our finding of low levels of satisfaction with the clinical care of patients with chronic pain is consistent with previous clinician surveys [7] . In a survey of Veterans Affairs clinicians, 73% moderately or strongly agreed that patients with chronic pain are a major source of frustration [13] . In a mailed survey of 111 primary care practitioners, low satisfaction rates with treating patients with chronic pain were reported among all providers, but the lowest rates of satisfaction were among those who were least likely to prescribe opioids [7] . In our survey, 82% of providers were reluctant to prescribe opioids to patients with CNCP. We observed that the overwhelming majority thought that the clinical practice should have a "consistent approach" to opioid prescribing. The lack of a standard approach to opioid prescribing among clinicians in a group practice presents challenges to the development and reinforcement of opioid agreements or behavioral guidelines with patients receiving opioids for CNCP. Additional work is needed to understand what consistent clinical approaches are and how they could assist clinicians in the care of CNCP patients on opioids.
The implementation of and adherence to guidelines with mandated prescribing limits for first-time prescriptions has been proposed as a way to standardize clinical practice while not imposing arbitrary dose limits on patients with CNCP. The CDC guideline states that in the setting of acute pain, opioid provision for "three days or less will often be sufficient; more than seven days will rarely be needed" [8] . This approach has been adopted voluntarily by emergency rooms in New York City and signed into law in Massachusetts [14] . Our data suggest that the onequarter of clinicians strongly disagree with dose limits. Legally mandated dosing limits of opioids could lead to increased health care utilization and cost, with patients returning for treatment of ongoing pain after a short duration of treatment has been exhausted. Some of these issues could be mitigated by leveraging existing technologies, such as electronic prescribing of opioids, which was allowed by the US Drug Enforcement Agency in 2010 but has not been widely adopted [15] .
Concerns about addiction, dependence, and opioid misuse are common among clinicians prescribing opioids [5] [6] [7] 16, 17] . The majority of respondents in our survey expressed concern about these issues, a concern that was greater among clinicians who knew of a patient who required medical attention for an opioid overdose. Awareness of the CDC guideline was associated with increased clinician worry over patients becoming dependent on opioids. We defined dependence as "tolerance and withdrawal symptoms on discontinuation." Opioid dependence can potentially develop after three days of continuous opioid use [18] . We defined addiction as "drug craving, obsessive thinking about the drug, loss of control, and compulsive use." Although opioid dependence is a clinically expected outcome of long-term opioid use for CNCP, addiction is not. Surveys in primary care have identified that the lower the concern for addiction, tolerance, and dependence, the more likely clinicians are to prescribe opioids for CNCP [16] . However, previous surveys have demonstrated that clinicians have an inadequate understanding of the difference between addiction and dependence [6] . This lack of understanding may be impacting prescribing behaviors. In a survey of 111 primary care providers, 89.2% of clinicians reported that the potential for patients to become addicted would have a moderate or large effect on opioid prescribing for CNCP [7] . Among CNCP patients with no history of current substance abuse or addiction, the rate of developing abuse or addiction with chronic opioid therapy may be as low as 0.19% [19] . The rate is 3.27% among unselected patients. A systematic review of long-term opioid management for CNCP identified the rate of opioid addiction to be 0.27% [20] . More recent studies have suggested that the prevalence of addiction is 14% to 19% among patients receiving opioids for chronic pain [21] . Screening patients with tools such as the Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R) [22] , the Opioid Risk Tool (ORT) [23] , and the Opioid Abuse Risk Screener [24] may help clinicians weigh the risks and benefits of initiating opioids for CNCP. However, alternatives to pain management for patients deemed higher risk based upon these tools remain limited in implementation or accessibility, and no studies have clearly demonstrated that these screening tools translate into alterations in prescribing patterns that reduce the risk for addiction, abuse, or misuse.
Almost three-quarters of clinicians endorsed that they were following the CDC guideline for prescribing opioids for chronic pain, but only 55% were enrolled in the state PDMP and few clinicians were prescribing the opioid antagonist naloxone. Naloxone provision has been associated with a reduction in opioid overdose mortality [25, 26] . The CDC guideline recommends offering naloxone when patients present with factors increasing the risk for opioid overdose including a history of overdose or substance use disorder, higher opioid dosages (50 MME/d), or concurrent benzodiazepine use [27] . Focus group work has identified that clinician barriers to prescribing naloxone included fear of offending patients, concerns about patients engaging in risky behavior, and the medicolegal implications of prescribing an "antidote" (naloxone) for the drug they are prescribing (opioid) [28] . In this study of 60 primary care patients receiving naloxone, 79% had a positive or neutral reaction to the naloxone prescription, 82% of patients filled the naloxone prescription, and 97% of them thought that naloxone should be available to patients prescribed opioids for pain [28] . When educating clinicians on the use and prescription of naloxone, discussion should emphasize that the term "overdose" is frequently interpreted as overconsumption when proper consumption may cause adverse health effects in the presence of medical comorbidities [29] . In this regard, naloxone can save lives from an overdose event when patients are using the opioids as prescribed. The Food and Drug Administration (FDA) approved an intranasal version of naloxone to increase the ease of administration [30] . This product increases the ease of administration by bystanders in the case of an overdose event. A greater number of prescribers, a greater number of pharmacies, and higher daily morphine milligram equivalents per day, all of which can be assessed through the PDMP, have been associated with an increased risk of opioid overdose deaths [31] . However, PDMP's have not been consistently shown to be associated with reduced opioid-related deaths [32] . In our survey, clinicians who knew of a patient who required medical attention for an opioid overdose had a higher likelihood of being enrolled in a PDMP.
Proposed solutions to mitigating the opioid crisis are legion. State-and systems-level interventions that have demonstrated promise for reducing inappropriate prescribing, "doctor shopping," and overdose include PDMPs, insurer strategies, pain clinic legislation, clinical guideline implementation, and naloxone distribution programs [33] . Some have proposed limiting opioid availability, predicated on the lack of evidence for the effectiveness of long-term opioid use for decreasing pain and improving function [34] [35] [36] . However, claims that opioids are ineffective for alleviating chronic pain have not been clearly substantiated [37] , and some reviews have suggested that they may be effective in this clinical context [20] . Balanced and multifaceted approaches are needed to avoid the unintended consequence of limiting opioid analgesics access to patients who would benefit from them. Education needs to be a cornerstone in our management of the opioid epidemic. Education can empower clinicians to make patientcentered decisions that incorporate an adequately assessed risk-benefit evaluation. In 2012, the FDA approved a shared Risk, Evaluation and Mitigation Strategy (REMS) requiring manufacturers of extendedrelease (ER) and long-acting (LA) opioid analgesics to fund accredited education on safe opioid prescribing practices for the 320,000 ER/LA opioid prescribers in the United States [38] . This education has been demonstrated to improve knowledge, attitudes, confidence, and self-reported clinical practice in safe opioid prescribing [39] . However, concerns have been raised about the voluntary nature of REMS education and the conflict of interest posed by having the pharmaceutical industry fund REMS [40] . Consistent with other clinician surveys [41] , less than one-half of respondents in our survey felt confidence in their ability to care for patients with CNCP. Awareness of the CDC guideline was associated with increased confidence in caring for patients with CNCP. However, only a minority sought education to help with opioid prescribing. Providing education on the best practices for opioid prescribing should occur at all levels of training and for all members of the medical care team [38] . Standardized approaches for tapering off opioids should also be developed and made accessible to prescribing clinicians. Education about nonopioid pain management strategies needs to be provided as these modalities are underutilized [42] . However, clinicians need to remain aware of the potential adverse health risks associated with nonopioid pain treatments [43] [44] [45] . Opportunities exist for improving, expanding, and disseminating nonpharmacologic techniques for CNCP. Increasing the accessibility and reimbursement for physical therapy [46] and cognitive behavior therapy [47] may benefit providers unsatisfied with the care delivered to patients with CNCP on opioids. Effective primary care clinic practice redesign efforts around opioid prescribing have been observed to follow six common change strategies: 1) providing leadership support; 2) revising and aligning clinic policies, patient agreements, and workflows; 3) implementing a registry tracking system; 4) conducting planned, patient-centered visits; 5) identifying resources for complex patients; and 6) measuring progress toward achieving clinic objectives [48] .
Our survey is one of the largest conducted assessing attitudes, beliefs, practice styles, and provider concerns regarding opioid prescribing. Although sampling was completed in a census format, survey conduct at a single institution is a limitation. We also do not have data available on the nonresponders, so we are unable to assess for the presence of nonresponse error. Additionally, comparisons made between individuals with awareness of the CDC guideline may be subject to response bias as awareness and familiarity with the guideline standards (e.g., screening for depression and substance abuse, nonconcomitant prescribing of benzodiazepines and opioids) may alter responses in favor of adherence to the guidelines, potentially overestimating effects.
Our survey suggests that clinicians continue to struggle with the practice of prescribing opioids to patients with CNCP. Opportunities exist to improve patient safety and clinician comfort through strategies that include clinician and patient education, increasing the ease of access to PDMPs [49] , and engagement in electronic prescribing of opioids. Concerns about patient safety can be leveraged to promote the implementation of opioid prescribing guidelines for chronic pain as clinician behavior and concerns are related to knowledge of overdose events. Congress should fund the Comprehensive Drug Abuse and Recovery Act of 2016, which requires the convening of a Pain Management Best Practices Inter-Agency Task Force with broad representation from the public and private sector [50] . The task force would be charged with identifying, reviewing, and determining if gaps or inconsistencies exist between best practices for acute and chronic pain management and proposing updates to best practices and recommendations on addressing gaps. Future research should evaluate the extent to which guideline implementation improves patient safety and provider satisfaction, the development of patient monitoring approaches that maximize patient safety while minimizing clinical burden, the evaluation of algorithms for approaches to opioid tapering, and clinical care pathways for managing patients with misuse and addiction [51] .
